Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials

Baxdrostat Granted FDA Priority Review for Hard-to-Control Hypertension, Could Be First-In-Class Therapy

News

Slideshow

Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.

Related Content

December 2nd 2025

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

The Priority Review decision is based on phase 3 results showing consistent SBP reductions across uncontrolled and treatment-resistant hypertension subgroups.

November 13th 2025

Bayer's Asundexian Reduces Ischemic Stroke Risk Without Raising Major Bleeding in Phase III Trial

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

November 24th 2025

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Topline data show the factor XIa inhibitor cut ischemic stroke risk without increasing ISTH major bleeding, pointing to a possible new option for secondary prevention.

September 24th 2025

Rising Youth Hypertension and Its Long-Term Impact on Coronary Disease: Two New Data Sets

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Dual GCG/GLP-1 Agonist Mazdutide 9 mg Produces 20% Weight Loss in Phase 3 Trial of Chinese Adults with Obesity

A 2-fold rise in pediatric hypertension over 2 decades and new long-term imaging data signal a need to rethink how early clinicians act on elevated BP.

Baxdrostat Granted FDA Priority Review for Hard-to-Control Hypertension, Could Be First-In-Class Therapy

GLORY-2 participants showed continuous weight loss through 60 weeks with no plateau; mazdutide also improved multiple cardiometabolic markers.

Related Content

December 2nd 2025

Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes

The Priority Review decision is based on phase 3 results showing consistent SBP reductions across uncontrolled and treatment-resistant hypertension subgroups.

November 13th 2025

Bayer's Asundexian Reduces Ischemic Stroke Risk Without Raising Major Bleeding in Phase III Trial

Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.

November 24th 2025

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Topline data show the factor XIa inhibitor cut ischemic stroke risk without increasing ISTH major bleeding, pointing to a possible new option for secondary prevention.

September 24th 2025

Rising Youth Hypertension and Its Long-Term Impact on Coronary Disease: Two New Data Sets

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Dual GCG/GLP-1 Agonist Mazdutide 9 mg Produces 20% Weight Loss in Phase 3 Trial of Chinese Adults with Obesity

A 2-fold rise in pediatric hypertension over 2 decades and new long-term imaging data signal a need to rethink how early clinicians act on elevated BP.